Author:
Bullement Ash,Underhill Stuart,Fougeray Ronan,Hatswell Anthony James
Subject
Gastroenterology,Oncology
Reference13 articles.
1. Randomized trial of TAS-102 for refractory metastatic colorectal cancer;Mayer;N Engl J Med,2015
2. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial;Yoshino;Lancet Oncol,2012
3. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer;Hoyle;Value Health,2013
4. TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the Phase III RECOURSE trial [abstract];Mayer;J Clin Oncol,2016
5. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Grothey;Lancet,2013
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献